Paul Catchpole, ABPI Director of Value and Access, comments on NHS England’s proposals for the future delivery of the Cancer Drugs Fund, published earlier today on their website.
Click here to read NHS England's proposal.
Paul Catchpole said: “This is welcome news and a move that the ABPI broadly supports, as long as cancer patients can continue to access the medicines they need.
“We have said all along that the Cancer Drugs Fund (CDF) was
nothing more than a sticking plaster, albeit one that has enabled thousands of patients to access cancer medicines, and that NICE, along with NHS England, needs to develop a longer-term sustainable solution to the evaluation and commissioning of cancer medicines. This move should help provide a much needed bridge to greater reform of NICE so that all patients can benefit from improved access to new medicines. We look to the current Accelerated Access Review to help galvanise this urgent requirement.
“In the context of the CDF, these proposals should help speed up NHS patient access to the latest medicines and help patients benefit from innovative cancer drugs that are routinely available in many other European countries. We are pleased to see that the new proposals intend to address some of the key areas for change that the ABPI has been calling for and in particular a new system aligned with NICE to deliver a more robust and rapid evaluation process, flexibilities around the use of the current end-of-life criteria and the introduction of conditional NICE approvals for promising medicines until additional evidence can be collected. There is more to be addressed but it is a very encouraging start."
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: